Johnson & Johnson (JNJ) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Johnson & Johnson (JNJ)

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

254.66

+9.78 (3.99%)

as of Jun 26, 2026, 8:00:00 pm Market Open.

696 watching

Investor Insights

Jun 28, 2026, 12:00 am

This summary was created by AI, based on 10 opinions in the last 12 months.

Johnson & Johnson (JNJ) has garnered a generally positive outlook from various experts, particularly highlighting its strong performance in pharmaceuticals and medical devices after a recent spin-off of its orthopedics division. The company's robust drug pipeline is considered one of the best in the industry, contributing to a resilient stock performance even amidst market volatility. While there is a legal overhang due to ongoing talcum powder lawsuits, experts suggest that this has diminished in significance. The company's valuation appears reasonable, and many experts encourage buying on weakness, reflecting confidence in future growth prospects. Overall, JNJ is seen as a solid investment, especially for those interested in dividend growth and long-term potential.

Consensus

Positive

Valuation

Fair Value

Similar

TOP PICK

One of his 2 favourite areas is health care because of the demographics. You can buy at a discount to the market.

BUY

There is competition in the stent market. The whole health-care sector is a bit of a puzzle. Has been executing very well, but money just doesn't seem to want to flow into health-care.

TOP PICK

One of a handful of AAA Company's out there. Great dividend history. Reasonable P/E valuation. Hasn't participated in the strong market over the course of the last year or so.

TOP PICK

A non cyclical stock. Pays a dividend yield in the healthcare sector.

HOLD

They've been groeing their market share by 20% throughout the last 4 years. Trading at evaluation standards that are fantastic, looks attractive for long-term hold, Drug companies are undervalued., could see some good gains.

BUY

In the long term, it's a great diversified play in the healthcare sector.

DON'T BUY

Has been stuck around $50 mark. Took a big jump when they first produced a stent but they now have competition, which is taking quite a bit of market share. Could see it go a bit lower.

TOP PICK

A contrarian play. Has performed very well from a financial perspective. Growth prospect is a very positive. Very good long-term value.

BUY

Trading at a discounted valuation. They are getting competition with their stents. At a decent valuation. Should see some upside from here.

BUY

Pharmaceutical stocks are defensive in nature.In this environment, nobody's buying them.Will be dead money in the short term.A good price to buy out for the long-term.

BUY

They have a huge consumer business.The drug sector has been sluggish.Longer term this should pick up.

WEAK BUY

Book value is about $8 a share. Drug companies always seem to do well.

BUY

Stable growth. Valuation may be a little high, but OK.

DON'T BUY

A defensive stock, so could lag a bit.

BUY

Great company. Into stents now which will be a big market opportunity.

Showing 586 to 600 of 626 entries

Most Recent Experts

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Kevin Simpson

Capital Wealth Planning

Bryn Talkington

Requisite Capital Management

Andrey Omelchak

LionGuard Capital Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Johnson & Johnson (JNJ)